Metformin Cuts Type 1 Insulin Use by 0.10 Units/kg a Day, Fails Clamp-Test Goal

4 articles · Updated · Okdiario · May 20

A 26-week randomized trial in 40 adults with long-term type 1 diabetes found metformin lowered total daily insulin use versus placebo by 0.10 units/kg/day—about 8 units for a 180-pound adult.
Clamp testing showed no significant improvement in hepatic insulin resistance, the study’s primary endpoint, and A1C plus continuous glucose-monitoring measures also did not significantly differ between groups.
Thirty-seven participants completed the trial, with no increase in hypoglycemia or ketoacidosis in either group; insulin adjustments were made by patients and clinicians, mirroring routine care but limiting causal interpretation.
Researchers said the insulin-sparing effect may reflect pathways beyond classic insulin sensitivity, noting higher GDF15 levels in the metformin group and ongoing work on mechanisms including gut microbes.
Metformin remains off-label for type 1 diabetes in the U.S., and the small adult-only study leaves open which patients might benefit most despite the potential to ease day-to-day insulin burden.

Metformin offers T1D patients fewer injections but no A1C change. Is this a true breakthrough or a risky trade-off?

Metformin slashes insulin needs for type 1 diabetics. If not by fixing resistance, what is the drug’s secret weapon?